Bain Capital Public Equity Management Ii, LLC Assembly Biosciences, Inc. Transaction History

Bain Capital Public Equity Management Ii, LLC

$1.99 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.87 - $17.29 $1.74 Million - $6.19 Million	-358,008 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$15.08 - $27.04 $2.45 Million - $4.38 Million	-162,165 Reduced 31.18%	358,008 $5.89 Million
Q2 2020 Aug 14, 2020	BUY	$14.57 - $23.96 $5.14 Million - $8.46 Million	352,959 Added 211.08%	520,173 $12.1 Million
Q1 2020 May 15, 2020	BUY	$10.27 - $21.23 $74,087 - $153,153	7,214 Added 4.51%	167,214 $2.48 Million
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $1.34 Million - $3.81 Million	160,000 New	160,000 $3.27 Million

Others Institutions Holding ASMB

# of Institutions

Shares Held

16.3K

Call Options Held

Put Options Held

ETF Managers Group, LLC Summit, NJ

16.3K
Shares

$243,419
0.0% of portfolio

View Full List

About ASSEMBLY BIOSCIENCES, INC.

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

More about ASMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Account